

REMARKS

The specification is amended above to insert a reference to related cases.

The Figure descriptions have been clarified.

Claims 1, 7, 11-18, 21-22 and 34-36 have been amended to conform the claims of the current divisional application to a non-elected/pursued invention of the parent case.

Claims 2, 4, 6, 8-10 and 23-31 have been cancelled without prejudice to the filing of future continuing applications.


No amendment of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, she is respectfully invited to call applicants' attorney.

Respectfully submitted,

Dated: December 2, 2003

(847)383-3372
(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA